Claims for Patent: 9,255,087

Summary for Patent: 9,255,087

Title:	Substituted indazole derivatives active as kinase inhibitors
Abstract:	Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.
Inventor(s):	Lombardi Borgia; Andrea (Paullo, IT), Menichincheri; Maria (Milan, IT), Orsini; Paolo (Legnano, IT), Panzeri; Achille (Merate, IT), Perrone; Ettore (Boffalora Sopra Ticino, IT), Vanotti; Ermes (Milan, IT), Nesi; Marcella (Saronno, IT), Marchionni; Chiara (Milan, IT)
Assignee:	NERVIANO MEDICAL SCIENCES S.R.L. (Nerviano (MI), IT)
Application Number:	14/534,617
Patent Claims:	1. A method for treating a disease selected from breast cancer, lung cancer, non-small cell lung cancer, colorectal cancer, prostate cancer, ovarian cancer, endometrial cancer, gastric cancer, clear cell renal cell carcinoma, uveal melanoma, multiple myeloma, rhabdomyosarcoma, Ewing's sarcoma, Kaposi's sarcoma, medulloblastoma, anaplastic large cell lymphoma, neuroblastoma, rhabdomyosarcoma, glioblastoma, inflammatory myofibroblastic tumor, melanomas, Ewing's sarcomas, retinoblastomas, squamous cell carcinoma, seminoma, teratocarcinoma, xeroderma pigmentosum, and thyroid follicular cancer, said method comprising administering to a patient in need thereof an amount of N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-- (tetrahydro-pyran-4-ylamino)-benzamide, or a pharmaceutically acceptable salt thereof, effective to treat said disease. 2. A method according to claim 1, wherein said disease is selected from breast cancer, non-small cell lung cancer, colorectal cancer, prostate cancer, melanoma, neuroblastoma, and glioblastoma. 3. A method according to claim 1, wherein said disease is selected from non-small cell lung cancer, colorectal cancer, neuroblastoma, and glioblastoma. 4. A method according to claim 1, wherein said disease is non-small cell lung cancer. 5. A method according to claim 1, wherein said disease is colorectal cancer. 6. A method according to claim 1, wherein said disease is neuroblastoma. 7. A method according to claim 1, wherein said disease is glioblastoma. 8. A method for treating a patient having cancer, wherein tumors from said patient are anaplastic lymphoma kinase positive, said method comprising administering to said patient an amount of N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-- (tetrahydro-pyran-4-ylamino)-benzamide, or a pharmaceutically acceptable salt thereof, that is effective to treat said cancer. 9. A method according to claim 8, wherein said cancer is selected from breast cancer, non-small cell lung cancer, colorectal cancer, prostate cancer, melanoma, neuroblastoma, and glioblastoma. 10. A method according to claim 8, wherein said cancer is selected from non-small cell lung cancer, colorectal cancer, neuroblastoma, and glioblastoma. 11. A method according to claim 8, wherein said cancer is non-small cell lung cancer. 12. A method according to claim 8, wherein said cancer is colorectal cancer. 13. A method according to claim 8, wherein said cancer is neuroblastoma. 14. A method according to claim 8, wherein said cancer is glioblastoma. 15. A method of inhibiting anaplastic lymphoma kinase activity, comprising contacting anaplastic lymphoma kinase with an effective amount of N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)- -2-(tetrahydro-pyran-4-ylamino)-benzamide, or a pharmaceutically acceptable salt thereof.